[1] WHO. Global tuberculosis report 2025. 2025. https://www.who.int/publications/i/item/9789240116924. [2025-11-13].
[2] WHO. The End TB Strategy. https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/the-end-tb-strategy. [2025-11-3].
[3] Garcia-Bereguiain MA, Rodriguez-Pazmiño AS, Franco-Sotomayor G, Orlando SA, González M, Ugarte-Gil C. "The end TB strategy" pathway in South America: out of track for 2025 milestones and 2035 eradication. Lancet Reg Health Am 2025;44:101045. https://doi.org/10.1016/j.lana.2025.101045.
[4] Clark RA, McQuaid CF, Richards AS, Bakker R, Sumner T, Prŷs-Jones TO, et al. The potential impact of reductions in international donor funding on tuberculosis in low-income and middle-income countries: a modelling study. Lancet Glob Health 2025;13(9):e1517 − 24. https://doi.org/10.1016/S2214-109X(25)00232-3.
[5] Zhang Y, Wang XL, Feng T, Fang CZ. Analysis of spatial-temporal distribution and influencing factors of pulmonary tuberculosis in China, during 2008-2015. Epidemiol Infect 2019;147:e25. https://doi.org/10.1017/s0950268818002765.
[6] National Health Commission of the People's Republic of China, National Development and Reform Commission of the People's Republic of China, Ministry of Education of the People's Republic of China, et al. National TB prevention and control plan (2024-2030). 2024. https://www.gov.cn/zhengce/zhengceku/202412/content_6991217.htm. (In Chinese). [2025-11-3].
[7] Xu CH, Zhao YL. Commit, invest and deliver: towards achieving end tuberculosis strategy goals through active case finding and preventive treatment in China. China CDC Wkly 2025;7(13):407 − 12. https://doi.org/10.46234/ccdcw2025.068.
[8] Zhou JN, Yuan Q, Huang QN, Wang QY, Huang HX, Chen W, et al. Implementation factors of tuberculosis control program in primary healthcare settings in China: a mixed-methods using the consolidated framework for implementation research framework. Infect Dis Poverty 2024;13(1):52. https://doi.org/10.1186/s40249-024-01222-3.
[9] Mao JJ, Zang X, Yue WL, Zhai PY, Zhang Q, Li CH, et al. Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study. BMJ Glob Health 2023;8(5):e012306. https://doi.org/10.1136/bmjgh-2023-012306.
[10] Ren JJ, Huang F, Chen HF, Zhang HM, Sun JW, Zhao AH, et al. Barriers to the acceptance of tuberculosis preventive treatment: a multicenter cross-sectional study in China. Biomed Environ Sci 2024;37(11):1303 − 9. https://doi.org/10.3967/bes2024.150.
[11] Gao L, Zhang HR, Xin HN, Liu JM, Pan SG, Li XW, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J 2018;52(6):1801470. https://doi.org/10.1183/13993003.01470-2018.
[12] WHO. Scaling up TB preventive treatment in China. Global Tuberculosis Report 2025 featured topics. 2025. https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2025/featured-topics/tb-preventive-treatment-in-china. [2025-11-3].
[13] Xiao X, Li ZP, Zhang HY, Xin X, Chen LL, Chen J, et al. Cross-sectional study of preventive treatment for students with latent tuberculosis infection in Shanghai, China. BMJ Open Respir Res 2025;12(1):e002799. https://doi.org/10.1136/bmjresp-2024-002799.
[14] Fekadu G, Tolossa T, Bekele F, Chen XH, He Y, Yu J, et al. Impact of all-oral bedaquiline-based shorter regimens in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. BMJ Glob Health 2025;10(4):e018220. https://doi.org/10.1136/bmjgh-2024-018220.
[15] Long Q, Guo L, Jiang WX, Huan ST, Tang SL. Ending tuberculosis in China: health system challenges. Lancet Public Health 2021;6(12):e948 − 53. https://doi.org/10.1016/S2468-2667(21)00203-6.
[16] Chen H, Cui Y, Liu KX, Lai CY, Wang Y, Chen QF, et al. China's initiatives and achievements in enhancing the professional capabilities of CDCs. China CDC Wkly 2024;6(38):979 − 81. https://doi.org/10.46234/ccdcw2024.203.
[17] Long Q, Jiang WX, Zhang H, Cheng J, Tang SL, Wang WB. Multi-source financing for tuberculosis treatment in China: key issues and challenges. Infect Dis Poverty 2021;10(1):17. https://doi.org/10.1186/s40249-021-00809-4.
[18] Ni SH, Chen G, Wang J, Li YH, Zhang H, Qu Y, et al. Assessment of public literacy in TB prevention and control in the National 13th five-year plan for tuberculosis prevention and control (2016-2020) in China. BMC Health Serv Res 2025;25(1):50. https://doi.org/10.1186/s12913-024-12155-w.
[19] Wei XL, Liang DB, Zhang ZT, Thorpe KE, Zhou LY, Zhao JM, et al. Active case finding using mobile vans with artificial intelligence aided radiology tests and sputum collection for rapid diagnostic tests to reduce tuberculosis prevalence among high-risk population in rural China: protocol for a pragmatic trial. PLoS One 2025;20(4):e0316073. https://doi.org/10.1371/journal.pone.0316073.
[20] Liu XQ, Thompson J, Dong HY, Sweeney S, Li X, Yuan YL, et al. Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial. Lancet Glob Health 2023;11(5):e693 − 703. https://doi.org/10.1016/S2214-109X(23)00068-2.